Zhao Cuihua, Cheng Guanchang, He Ruili, Guo Hongyu, Li Yanming, Lu Xueli, Zhang Yuan, Qiu Chunguang
Department of Cardiology, Henan University Huaihe Hospital, Kaifeng, Henan 475000, P.R. China ; Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.
Department of Cardiology, Henan University Huaihe Hospital, Kaifeng, Henan 475000, P.R. China.
Exp Ther Med. 2015 Jun;9(6):2401-2405. doi: 10.3892/etm.2015.2401. Epub 2015 Apr 1.
The aim of this study was to investigate the effect of different routes of tirofiban injection on the function of the left ventricle and the prognosis of patients with myocardial infarction (MI) treated with percutaneous coronary intervention (PCI). Ninety-five patients with MI treated with PCI were divided into two groups [coronary (n=49) and intravenous (n=46)] according to the injection route. A comparison of the left ventricular function and prognosis was made between the two groups following PCI. The success rate of PCI in the coronary group was 97.96%, which was higher than that in the intravenous group (P<0.05). No significant differences were identified in the platelet count (PLT) and platelet aggregation rate (PAR) between the two groups prior to the tirofiban injection. Following the tirofiban injection, the PLT decreased markedly in both groups, with no significant differences between them. The PAR also decreased significantly in the two groups; however, the value in the coronary group was lower than that in the intravenous group (P<0.05). The improvements in the thrombolysis in MI grades, left ventricular ejection fraction and left ventricular diastolic function were greater in the coronary group than those in the intravenous group (P<0.05). All patients received follow-up for 30 days and the incidence of bleeding in the coronary group was lower than that in the intravenous group (P<0.05). No significant differences were recorded in the recurrence rates of MI, arrhythmia, myocardial ischemia, thrombocytopenia and mortality between the two groups. In conclusion, the administration of tirofiban into the coronary artery could effectively improve the blood flow, left ventricular function and prognosis of patients with MI treated with PCI.
本研究旨在探讨替罗非班不同注射途径对接受经皮冠状动脉介入治疗（PCI）的心肌梗死（MI）患者左心室功能及预后的影响。95例接受PCI治疗的MI患者根据注射途径分为两组[冠状动脉组（n = 49）和静脉组（n = 46）]。PCI术后对两组患者的左心室功能及预后进行比较。冠状动脉组PCI成功率为97.96%，高于静脉组（P<0.05）。替罗非班注射前两组患者的血小板计数（PLT）和血小板聚集率（PAR）无显著差异。替罗非班注射后，两组PLT均显著下降，两组间无显著差异。两组PAR也显著下降；然而，冠状动脉组的值低于静脉组（P<0.05）。冠状动脉组在心肌梗死溶栓分级、左心室射血分数和左心室舒张功能方面的改善大于静脉组（P<0.05）。所有患者均随访30天，冠状动脉组出血发生率低于静脉组（P<0.05）。两组间MI复发率、心律失常、心肌缺血、血小板减少症和死亡率无显著差异。总之，冠状动脉内给予替罗非班可有效改善接受PCI治疗的MI患者的血流、左心室功能及预后。
